Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that causes demyelination, axonal degeneration, and astrogliosis, resulting in progressive neurological disability.
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used disease model for MS, which is mainly mediated by specifically sensitized CD4+T cells. The EAE model can simulate many phenotypes of human MS, such as weakness in the tail or legs, walking problems, staggering gait, and paralysis. GemPharmatech has successfully developed EAE model, which can be used to evaluate the preclinical efficacy of MS therapies.
Characteristics of EAE mouse model：
- Highincidence rate: The model shows a significant paralysis phenotype in mice.
- High stability: The EAE score remains stable, with disease onset starting on day 11 and entering a plateau phase on day 15, which can be sustained until day 50.
- GemPharmatech can offer a one-stop solution for preclinical MS drugs evaluation.